Clinical Trial Update: A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function [Phase 1]

View source ↗

Summary

Pfizer conducted a Phase 1 safety and tolerability study of CP-690,550 (tofacitinib) in people with hepatic impairment and those with normal liver function to c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Insufficiency

Drugs mentioned

• CP-690,550 (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Hepatic Insufficiency | Phase 1 | Status: COMPLETED